Lv6
2050 积分 2022-09-15 加入
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
2天前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
2天前
已完结
BNC2 as a novel driver of pancreatic cancer progression through transcriptional regulation of COL3A1 and epithelial-to-mesenchymal transition
1个月前
已完结
Prevalence and Trend of Biopsy-Proven IgA Nephropathy in China: A Systematic Review
1个月前
已完结
Cytokeratin fragments in the serum: Their utility for the management of oral cancer
1个月前
已关闭
Long-term outcomes of IgA nephropathy in China
1个月前
已完结
Time-Varying Proteinuria and Progression of IgA Nephropathy: A Cohort Study
1个月前
已完结
Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population
1个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
2个月前
已完结
Transcriptomics-Guided High-Throughput Drug Screening Identifies Potent Therapies for P53 Pathway Alterated DIPG/DMG
2个月前
已关闭
皖公网安备34019202002308
